Insulin

Authoritative sources

• Wikidata (Q7240673)
• MeSH (D007328)
• Wikipedia

Evidence base

• Randomized Controlled Trial · 2026

  Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

  Lancet (London, England) · Rosenstock J, Billings LK, Gajria R, Giorgino F, et al.

• Meta-Analysis · 2025

  Pharmacological interventions for the acute treatment of hyperkalaemia: A systematic review and meta-analysis

  Resuscitation · Jessen MK, Andersen LW, Djakow J, Chong NK, et al.

• Phase III Clinical Trial · 2025

  Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy

  The New England journal of medicine · Rosenstock J, Bailey T, Connery L, Miller E, et al.

• Randomized Controlled Trial · 2025

  Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial

  Lancet (London, England) · Hannon TS, Chao LC, Barrientos-Pérez M, Pamidipati KC, et al.

• Randomized Controlled Trial · 2025

  Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial

  The lancet. Diabetes & endocrinology · Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fernández Landó L, et al.

• Randomized Controlled Trial · 2025

  Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial

  Diabetes care · Mari A, Stefanski A, van Raalte DH, Ma X, et al.

• Randomized Controlled Trial · 2025

  Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

  The lancet. Diabetes & endocrinology · Guo L, Dong X, Ma J, Liu M, et al.

• Systematic Review · 2024

  Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials

  Diabetes, obesity & metabolism · Ayesh H, Suhail S, Ayesh S, Niswender K

• Phase III Clinical Trial · 2024

  Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment

  The New England journal of medicine · Wysham C, Bajaj HS, Del Prato S, Franco DR, et al.

• Randomized Controlled Trial · 2024

  Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)

  The Journal of clinical endocrinology and metabolism · Frias JP, De Block C, Brown K, Wang H, et al.

• Randomized Controlled Trial · 2023

  Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial

  JAMA · Lingvay I, Asong M, Desouza C, Gourdy P, et al.

• Meta-Analysis · 2023

  Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials

  Reproductive biology and endocrinology : RB&E · Greff D, Juhász AE, Váncsa S, Váradi A, et al.

• Randomized Controlled Trial · 2023

  Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial

  JAMA · Rosenstock J, Frías JP, Rodbard HW, Tofé S, et al.

• Meta-Analysis · 2022

  Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis

  BMJ (Clinical research ed.) · Ye W, Luo C, Huang J, Li C, et al.

• Meta-Analysis · 2022

  Omega-3 supplementation and diabetes: A systematic review and meta-analysis

  Critical reviews in food science and nutrition · Delpino FM, Figueiredo LM, da Silva BGC, da Silva TG, et al.

• Randomized Controlled Trial · 2022

  Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial

  JAMA · Dahl D, Onishi Y, Norwood P, Huh R, et al.

• Randomized Controlled Trial · 2022

  Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

  The lancet. Diabetes & endocrinology · Heerspink HJL, Sattar N, Pavo I, Haupt A, et al.

• Randomized Controlled Trial · 2022

  Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

  The lancet. Diabetes & endocrinology · Battelino T, Bergenstal RM, Rodríguez A, Fernández Landó L, et al.

• Meta-Analysis · 2021

  Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials

  Nutrients · Veronese N, Dominguez LJ, Pizzol D, Demurtas J, et al.

• Randomized Controlled Trial · 2021

  Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

  Lancet (London, England) · Ludvik B, Giorgino F, Jódar E, Frias JP, et al.

Where Insulin appears on Kindr Health